Healio spoke with Chakra Chaulagain, MD, about preliminary phase 3 results from the IsKia trial presented at ASH Annual Meeting and Exposition.
The trial assessed the safety and efficacy of isatuximab (Sarclisa, Sanofi)-carfilzomib-lenalidomide-dexamethasone (IsaKRd) in patients with newly diagnosed multiple myeloma compared with KRd alone.
“What the study showed was that the quadruplet therapy of isatuximab when combined with the triplet of KRd was associated with much higher [minimal residual disease (MRD)] negativity after the consolidation,” Chaulagain, director of the myeloma
